



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid
Drug Utilization Review (DUR) Board

2pm

Thursday, February 19, 2015
DMAS Board Room 13th Floor

Agenda

1. Call to Order and Introductions – Randy Ferrance, MD, Chair
2. Minutes
 - a. Approval of Minutes from November 20, 2014 meeting
3. New Drugs
 - a. Contrave[®] (naltrexone/bupropion)
 - b. Esbriet[®] (pirfenidone)
 - c. Ofev[®] (nintedanib)
 - d. Lynparza[™] (olaparib)
 - e. Soolantra[®] (ivermectin)
 - f. Tybost[®] (cobicistat)
 - g. New drugs: PDL-eligible; physician-administered injectables
4. Service Authorizations
 - a. Jakafi – new FDA approved indication for polycythemia vera
 - b. Imbruvica – now approved for Waldenstrom's macroglobulinemia
5. Reports
 - a. ProDUR
 - b. RetroDUR
 - c. Utilization Analysis
 - d. Top Diagnoses by Age
 - e. AAP Report
6. Future Topics
 - a. Analysis of Compounded Medications – *follow up*
 - b. Morphine Equivalent Dosing for Narcotics
7. First Data Bank's *Alert Space* Clinical Modules
8. Other Business
9. Adjournment